Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques

TO THE EDITOR: Neurotoxicity from anti-CD19 chimeric antigen receptor (CAR) T cells, an effective immunotherapy for refractory B-cell malignancies,[1][1][⇓][2][⇓][3][⇓][4][⇓][5]-[6][6] is common and poorly understood. Commonly manifesting as headache, delirium, language disturbances and